Fig. 3From: Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia modelsTumor growth inhibition in a MV4-11 subcutaneous model and TTE analysis of survival in b MV4-11 and c MOLM-13 orthotopic models (n = 10 mice per group). Combination treatment resulted in superior anti-tumor activity and enhanced survival. See text for details. TTE time-to-eventBack to article page